GAITHERSBURG, Md. - Emergent BioSolutions Inc. (NYSE: EBS), a pharmaceutical company with a market capitalization of approximately $510 million, has acquired exclusive commercial rights for KLOXXADO® ...

on Tuesday announced that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada for KLOXXADO or naloxone HCl Nasal Spray from Hikma Pharmaceuticals.

HCL Technologies shares dropped 9.23% after the company reported a 6% net profit growth for Q3 at Rs 4,591 crore. Revenue rose to Rs 29,890 crore. New deal bookings reached $2.1 billion. Analysts ...

Alongside over-the-counter NARCAN ® Nasal Spray 4 mg, prescription KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg will expand Emergent's ability to distribute multiple life-saving opioid overdose ...

(NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO® (naloxone HCl) Nasal Spray ...

Analysts noted that despite delivering a solid financial performance led by a sharp uptick in deal wins, both TCS and HCL Tech faced pressure due to higher expectations on the Street. India's ...

Since using black market nasal tanning spray, Harper has had facial flushes, acne, and more freckles. The illegal spray can have serious side effects, according to the Therapeutic Goods ...

Hikma will continue producing its 8 mg naloxone HCl nasal spray in its Columbus, Ohio manufacturing facility and will provide it to Emergent as its exclusive commercial partner. This partnership ...

Hikma will continue producing its 8 mg naloxone HCl nasal spray in its Columbus, Ohio manufacturing facility and will provide it to Emergent as its exclusive commercial partner. "We are thrilled ...

Under the terms of the six-year agreement, Emergent will add KLOXXADO® Nasal Spray to its naloxone product portfolio and will be responsible for all North America product sales and marketing. Hikma ...

(NYSE: EBS), a pharmaceutical company with a market capitalization of approximately $510 million, has acquired exclusive commercial rights for KLOXXADO® (naloxone HCl) Nasal Spray 8 mg in the ...